Speaker Profile

Co-founder & CEO, AiVF

Daniella Gilboa is an embryologist, biostatistician, entrepreneur and an IVF researcher. Her vast experience in embryology led her to co-found AiVF, together with two renowned IVF physicians, Prof. Daniel Seidman and Prof. Eyal Schiff. AiVF develops a data and AI-driven comprehensive platform for IVF treatment process. AiVF’s first application of its technology being applied to the process of embryo selection and through Daniella’s notoriety in the IVF industry AiVF is collaborating with international institutions such as Stanford, Weill Cornell Medicine and one of the leading IVF clinics, IVI Valencia. Prior to AiVF Daniella worked as a Global Senior Biostatistician at Teva Pharmaceuticals and as a senior embryologist at Assuta, Israel’s leading IVF clinics which completes on 15,000 IVF cycles per year. Her experience as a biostatistician and seasoned embryologist led her to co-found AiVF in order to revolutionize the way IVF is done today. Daniella speaks worldwide on IVF in general as well utilizing deep technology in making IVF more effective and accessible.

Clinical Dx Showcase:

Founded by seasoned IVF veterans, AiVF develops an AI-powered, end-to-end treatment platform for the IVF (in vitro fertilization) treatment. Our mission is to make IVF more effective, accessible and affordable to an overwhelming underserved population.

AiVF - Disrupting IVF
Daniella’s presentation will include her personal story and why AiVF was founded. It will also cover the challenges of the IVF industry and how AiVF addresses those challenges through its end-to-end AI-driven decision platform with various application from embryo selection to non-invasive genetic testing. The presentation will also cover some of the research and results we are conducting around embryo selection with leading institutions such as Stanford, Cornell Weill Medicine and IVI Valencia IVF clinic.

 Session Abstract – PMWC Silicon Valley

The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.